Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mulligan

Showing results (521-530 of 529) with videos related to

Pageof 53
Sort By:
You have reached the last page of results.This site can display upto 529 results.
NPJ Vaccines|July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
The New England Journal of Medicine|June 10, 2026
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel DiseaseNima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Nature Medicine|August 28, 2023
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trialAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 53

Showing results (521-530 of 529) with videos related to

Sort By:
Pageof 53
You have reached the last page of results.This site can display upto 529 results.
NPJ Vaccines|July 11, 2023
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
The New England Journal of Medicine|June 10, 2026
Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel DiseaseNima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, et al.
Open Forum Infectious Diseases|March 4, 2015
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical TrialMark J Mulligan, David I Bernstein, Sharon Frey, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Nature Medicine|August 28, 2023
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trialAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 53